JNJ Add to watchlist $229.11 5.10 (-2.18%) Last updated: Jun 18, 2026 18:31
52-Week Range
$229.11
$149.04 $229.11 $251.71

Fundamentals Overview

Johnson & Johnson is near the high of its 52-week range with premium valuation, trending downward today.

Valuation premium

P/E 26.6 P/B 6.9 P/S 5.72

Intrinsic value (DCF)

+40.9% upside vs price

Profitability

Net margin 21.8%

Risk (Beta)

0.26 — lower vol

Earnings & growth

EPS $8.60 Rev -2% Profit +2.3% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 67% confidence Risk: Lower Volatility — Beta 0.26. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +40.9% upside vs price · Analyst grade: B+ · Sentiment improving (2 upgrades)

Pressures (Sell):

3M vs S&P 500: -17.3%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$551.51B
P/E (TTM)
26.63
EPS (TTM)
$8.60
Dividend Yield
2.29%
52-Week Range
$149.04 - $251.71
Volume vs Avg
N/A
Beta
0.26

About

Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Ken...
Sector: Healthcare
Headquarters: US
Employees: 138,100
IPO Date: Jan 1943
Website: www.jnj.com
Beta: 0.26 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 8, Equal Weight: 5, Hold: 4, Market Perform: 1, Neutral: 3, Outperform: 4, Overweight: 4, Sector Outperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $322.90; current price is $229.11. That’s a +40.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 26.63
DCF value (model) $322.90 (40.9% upside)
PEG (TTM) N/A
P/B (TTM) 6.9
P/S (TTM) 5.72
P/FCF (TTM) 30.99
Liquidity & enterprise
Current Ratio (TTM) 1.03
Quick Ratio (TTM) 0.77
Cash Ratio (TTM) 0.38
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 21.83%
Gross margin (TTM) 69.12%
Operating margin (TTM) 26.87%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for JNJ.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 8Equal Weight 5Hold 4Market Perform 1Neutral 3Outperform 4Overweight 4Sector Outperform 1
2 upgrades, 0 downgrades
Price Target Consensus
Current $229.11
Median $255.00
Consensus $251.55
Low consensus $208.00
High consensus $283.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Leerink Partners upgrade Market Perform Outperform 2026-05-13
Stifel maintain Hold Hold 2026-04-15
Barclays maintain Equal Weight Equal Weight 2026-04-15
Wells Fargo maintain Overweight Overweight 2026-04-15
Morgan Stanley maintain Overweight Overweight 2026-04-10
RBC Capital maintain Outperform Outperform 2026-03-30
Barclays maintain Equal Weight Equal Weight 2026-03-19
HSBC maintain Buy Buy 2026-03-17
Citigroup maintain Buy Buy 2026-03-11
JP Morgan maintain Neutral Neutral 2026-03-05
RBC Capital maintain Outperform Outperform 2026-02-03
Morgan Stanley upgrade Equal Weight Overweight 2026-01-28
Freedom Capital Markets maintain Hold Hold 2026-01-27
Freedom Broker maintain Hold Hold 2026-01-27
Guggenheim maintain Buy Buy 2026-01-23
B of A Securities maintain Neutral Neutral 2026-01-22
Morgan Stanley maintain Equal Weight Equal Weight 2026-01-22
Citigroup maintain Buy Buy 2026-01-22
Stifel maintain Hold Hold 2026-01-22
Wells Fargo maintain Overweight Overweight 2026-01-22
TD Cowen maintain Buy Buy 2026-01-22
Scotiabank maintain Sector Outperform Sector Outperform 2026-01-22
Bernstein maintain Market Perform Market Perform 2026-01-09
Barclays maintain Equal Weight Equal Weight 2025-12-30
Goldman Sachs maintain Buy Buy 2025-12-19
B of A Securities maintain Neutral Neutral 2025-12-15
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
Citigroup maintain Buy Buy 2025-12-11
RBC Capital maintain Outperform Outperform 2025-12-11
Guggenheim maintain Buy Buy 2025-12-05